SEC Comment Letter 0000000000-22-013474 to Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc.
Date: Dec. 14, 2022 · CIK: 0001808898 · Accession: 0000000000-22-013474
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268763
Letter
United States securities and exchange commission logo December 14, 2022 Jerel Banks, M.D. Chief Executive Officer Benitec Biopharma Inc. 3940 Trust Way Hayward, California 94545 Re:Benitec Biopharma Inc. Registration Statement on Form S-1 Filed December 13, 2022 File No. 333-268763 Dear Jerel Banks: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Louis Rambo, Esq.
Show Raw Text
United States securities and exchange commission logo
December 14, 2022
Jerel Banks, M.D.
Chief Executive Officer
Benitec Biopharma Inc.
3940 Trust Way
Hayward, California 94545
Re:Benitec Biopharma Inc.
Registration Statement on Form S-1
Filed December 13, 2022
File No. 333-268763
Dear Jerel Banks:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Louis Rambo, Esq.